Skip Nav Destination
Issues
15 May 2011
-
Cover Image
Cover Image
Distribution of actin and MET in PC3 cells stimulated with hepatocyte growth factor. Actin in shown in red, MET is shown in green, and nuclei are show in blue (DAPI). The yellow areas indicate coexpression of actin and MET suggestive of focal adhesion plaques. For further details, please see Jensen and coworkers on page 3112 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
Special Report
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Lisa H. Butterfield; A. Karolina Palucka; Cedrik M. Britten; Madhav V. Dhodapkar; Leif Håkansson; Sylvia Janetzki; Yutaka Kawakami; Thomas-Oliver Kleen; Peter P. Lee; Cristina Maccalli; Holden T. Maecker; Vernon C. Maino; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Graham Pawelec; Douglas M. Potter; Licia Rivoltini; Lupe G. Salazar; Dolores J. Schendel; Craig L. Slingluff, Jr; Wenru Song; David F. Stroncek; Hideaki Tahara; Magdalena Thurin; Giorgio Trinchieri; Sjoerd H. van Der Burg; Theresa L. Whiteside; Jon M. Wigginton; Francesco Marincola; Samir Khleif; Bernard A. Fox; Mary L. Disis
Human Cancer Biology
Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells
Ana R. Jensen; Saito Y. David; Chuanhong Liao; Jinlu Dai; Evan T. Keller; Hikmat Al-Ahmadie; Kelly Dakin-Haché; Peter Usatyuk; Margarit F. Sievert; Gladell P. Paner; Soheil Yala; Gustavo M. Cervantes; Viswanathan Natarajan; Ravi Salgia; Edwin M. Posadas
Cancer Therapy: Preclinical
Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations
Francesco Galimi; Davide Torti; Francesco Sassi; Claudio Isella; Davide Corà; Stefania Gastaldi; Dario Ribero; Andrea Muratore; Paolo Massucco; Dimitrios Siatis; Gianluca Paraluppi; Federica Gonella; Francesca Maione; Alberto Pisacane; Ezio David; Bruno Torchio; Mauro Risio; Mauro Salizzoni; Lorenzo Capussotti; Timothy Perera; Enzo Medico; Maria Flavia Di Renzo; Paolo M. Comoglio; Livio Trusolino; Andrea Bertotti
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
Loredana Santo; Teru Hideshima; Diana Cirstea; Madhavi Bandi; Erik A. Nelson; Gullu Gorgun; Scott Rodig; Sonia Vallet; Samantha Pozzi; Kishan Patel; Christine Unitt; Matt Squires; Yiguo Hu; Dharminder Chauhan; Anuj Mahindra; Nikhil C. Munshi; Kenneth C. Anderson; Noopur Raje
The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
Hiroshi Tanaka; Miyuki Yoshida; Hiromi Tanimura; Toshihiko Fujii; Kiyoaki Sakata; Yukako Tachibana; Jun Ohwada; Hirosato Ebiike; Shino Kuramoto; Keiichi Morita; Yasushi Yoshimura; Toshikazu Yamazaki; Nobuya Ishii; Osamu Kondoh; Yuko Aoki
Imaging, Diagnosis, Prognosis
Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib
Linda Mileshkin; Rodney J. Hicks; Brett G.M. Hughes; Paul L.R. Mitchell; Veena Charu; Barbara J. Gitlitz; David Macfarlane; Benjamin Solomon; Lukas C. Amler; Wei Yu; Andrea Pirzkall; Bernard M. Fine
Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification
Kengo Takeuchi; Manabu Soda; Yuki Togashi; Emiko Sugawara; Satoko Hatano; Reimi Asaka; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Blood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer
Thomas Zander; Andrea Hofmann; Andrea Staratschek-Jox; Sabine Classen; Svenja Debey-Pascher; Daniela Maisel; Sascha Ansén; Moritz Hahn; Marc Beyer; Roman K. Thomas; Birgit Gathof; Cornelia Mauch; Karl-Stefan Delank; Walburga Engel-Riedel; H.-Erich Wichmann; Erich Stoelben; Joachim L. Schultze; Jürgen Wolf
Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer
Jone Trovik; Elisabeth Wik; Ingunn M. Stefansson; Janusz Marcickiewicz; Solveig Tingulstad; Anne C. Staff; Tormund S. Njolstad; MoMaTec Study Group; Ingrid Vandenput; Frederic Amant; Lars A. Akslen; Helga B. Salvesen
Cancer Therapy: Clinical
Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
Tracy Tang; Jean Y. Tang; Dongwei Li; Mike Reich; Christopher A. Callahan; Ling Fu; Robert L. Yauch; Frank Wang; Karen Kotkow; Kris S. Chang; Elana Shpall; Angela Wu; Lee L. Rubin; James C. Marsters, Jr.; Ervin H. Epstein, Jr.; Ivor Caro; Frederic J. de Sauvage
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Beata Holkova; E. Brent Perkins; Viswanathan Ramakrishnan; Mary Beth Tombes; Ellen Shrader; Neha Talreja; Martha D. Wellons; Kevin T. Hogan; G. David Roodman; Domenico Coppola; Loveleen Kang; Jana Dawson; Robert K. Stuart; Cody Peer; William D. Figg, Sr.; Sarah Kolla; Austin Doyle; John Wright; Daniel M. Sullivan; John D. Roberts; Steven Grant
A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer
Heather L. McArthur; Hope Rugo; Benjamin Nulsen; Laura Hawks; Jill Grothusen; Michelle Melisko; Mark Moasser; Matthew Paulson; Tiffany Traina; Sujata Patil; Qin Zhou; Richard Steingart; Chau Dang; Monica Morrow; Peter Cordeiro; Monica Fornier; John Park; Andrew Seidman; Diana Lake; Theresa Gilewski; Maria Theodoulou; Shanu Modi; Gabriella D'Andrea; Nancy Sklarin; Mark Robson; Mary Ellen Moynahan; Steven Sugarman; Jane E. Sealey; John H. Laragh; Carmen Merali; Larry Norton; Clifford A. Hudis; Maura N. Dickler
MHC Class I–Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer
Michael A. Morse; Angeles A. Secord; Kimberly Blackwell; Amy C. Hobeika; Gomathinayagam Sinnathamby; Takuya Osada; Julie Hafner; Mohan Philip; Timothy M. Clay; H. Kim Lyerly; Ramila Philip
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
David Olmos; Douglas Barker; Rohini Sharma; Andre T. Brunetto; Timothy A. Yap; Anne B. Taegtmeyer; Jorge Barriuso; Hanine Medani; Yan Y. Degenhardt; Alicia J. Allred; Deborah A. Smith; Sharon C. Murray; Thomas A. Lampkin; Mohammed M. Dar; Richard Wilson; Johann S. de Bono; Sarah P. Blagden
Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro; Raoul Tibes; Michael S. Gordon; Bryan Y. Wong; Joseph Paul Eder; Mitesh J. Borad; David S. Mendelson; Nicholas J. Vogelzang; Bruno R. Bastos; Glen J. Weiss; Cristian Fernandez; William Sutherland; Hitoshi Sato; William E. Pierceall; David Weaver; Scott Slough; Ernesto Wasserman; Donald W. Kufe; Daniel Von Hoff; Takumi Kawabe; Sunil Sharma
Predictive Biomarkers and Personalized Medicine
Molecular Karyotypes of Hodgkin and Reed–Sternberg Cells at Disease Onset Reveal Distinct Copy Number Alterations in Chemosensitive versus Refractory Hodgkin Lymphoma
Marilyn L. Slovak; Victoria Bedell; Ya-Hsuan Hsu; Dolores B. Estrine; Norma J. Nowak; Maria L. Delioukina; Lawrence M. Weiss; David D. Smith; Stephen J. Forman
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Maarten J. Deenen; Jolien Tol; Artur M Burylo; Valerie D. Doodeman; Anthonius de Boer; Andrew Vincent; Henk-Jan Guchelaar; Paul H.M. Smits; Jos H. Beijnen; Cornelis J.A. Punt; Jan H.M. Schellens; Annemieke Cats
Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer
Peter P. Grimminger; Peter Danenberg; Kathrin Dellas; Dirk Arnold; Claus Rödel; Jean-Pascal Machiels; Karin Haustermans; Annelies Debucquoy; Vaneja Velenik; Christine Sempoux; Matej Bracko; Arnulf H. Hölscher; Robert Semrau; Dongyun Yang; Kathleen Danenberg; Heinz-Josef Lenz; Daniel Vallböhmer
Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib
Patrick G. Morris; Carol Chen; Richard Steingart; Martin Fleisher; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Alyson Abbruzzi; Robert Lehman; Sujata Patil; Maura Dickler; Heather L. McArthur; Eric Winer; Larry Norton; Clifford A. Hudis; Chau T. Dang
Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene
Naiyer A. Rizvi; Valerie Rusch; William Pao; Jamie E. Chaft; Marc Ladanyi; Vincent A. Miller; Lee M. Krug; Christopher G. Azzoli; Manjit Bains; Robert Downey; Raja Flores; Bernard Park; Bhuvanesh Singh; Maureen Zakowski; Robert T. Heelan; Ronglai Shen; Mark G. Kris
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds